Opthea raised $113 million in an institutional share placement that will be used to fund further phase 3 development of sozinibercept (OPT-302), a treatment for vision-robbing disease wet age ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.